Mankind Pharma credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
6,3126,3128,511207170
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4,2914,2916,266−3,249−1,358
0.38×0.38×0.58×0.02×0.02×
0.26×0.26×0.43×−0.34×−0.18×
1.74×1.74×2.82×0.08×0.09×
1.05×1.19×2.08×−1.28×−0.71×
4.27×4.27×5.58×63.73×35.41×
26.1%27.6%36.9%2.1%2.2%
As filed — company-reported covenants
—0.39×0.59×——
—0.47×0.60×——
—4.09×130.55×——
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANKIND₹2,469.30

Mankind Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹1.02L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Total Debt170.4207.28,511.56,311.56,311.5
Net Debt-1,358.3-3,248.96,266.14,291.54,291.5
Total Debt/Equity0.020.020.580.380.38
Net Debt/Equity-0.18-0.340.430.260.26
Total Debt/EBITDA0.090.082.821.741.74
Net Debt/EBITDA-0.71-1.282.081.191.05
Interest Coverage (EBIT/Interest)35.4163.735.584.274.27
Total Debt/Total Capital %2.192.1236.8827.5926.12
As Filed — company-reported covenants
Debt/Equity (as filed)——0.590.39—
Debt Service Coverage (as filed)——0.600.47—
Interest Service Coverage (as filed)——130.554.09—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.